121 related articles for article (PubMed ID: 11464201)
1. Management of cutaneous T-cell lymphoma: The future is here.
Wood GS
J Am Acad Dermatol; 2001 Aug; 45(2):317. PubMed ID: 11464201
[No Abstract] [Full Text] [Related]
2. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
Yoo EK; Cassin M; Lessin SR; Rook AH
J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
[TBL] [Abstract][Full Text] [Related]
3. Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.
Richardson SK; McGinnis KS; Shapiro M; Lehrer MS; Kim EJ; Vittorio CC; Junkins Hopkins JM; Rook AH
J Cutan Med Surg; 2003; 7(4 Suppl):8-12. PubMed ID: 12958701
[No Abstract] [Full Text] [Related]
4. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome.
Bouwhuis SA; Markovic SN; McEvoy MT; Pittelkow MR
Mayo Clin Proc; 2002 Feb; 77(2):197-200. PubMed ID: 11838656
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
6. Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis.
Durgin JS; Jariwala NN; Wysocka M; Zhang KK; Maity A; Benoit B; Plastaras JP; Lewis DJ; Rosenthal JM; Teague JE; Berg S; Del Guzzo C; Kim EJ; Vittorio C; Haun PL; Samimi SS; Villasenor-Park J; Inverso J; Clark RA; Rook AH
JAMA Dermatol; 2021 Jan; 157(1):90-95. PubMed ID: 33112366
[TBL] [Abstract][Full Text] [Related]
7. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response.
Vonderheid EC; Bigler RD; Greenberg AS; Neukum SJ; Micaily B
Am J Clin Oncol; 1994 Jun; 17(3):255-63. PubMed ID: 8192114
[TBL] [Abstract][Full Text] [Related]
8. From single-cell signature to prognostic factors: the case of Sézary syndrome.
Scala E; Narducci MG; Russo G
Expert Rev Clin Immunol; 2012 Nov; 8(8):699-701. PubMed ID: 23167680
[No Abstract] [Full Text] [Related]
9. Sézary syndrome: a summary.
Bouwhuis S; Davis MD
Dermatol Nurs; 2001 Jun; 13(3):205-7, 230. PubMed ID: 11917454
[TBL] [Abstract][Full Text] [Related]
10. Sézary syndrome: diagnostic criteria and therapeutic options.
Russell-Jones R; Whittaker S
Semin Cutan Med Surg; 2000 Jun; 19(2):100-8. PubMed ID: 10892711
[TBL] [Abstract][Full Text] [Related]
11. Extracorporeal photopheresis in Sézary syndrome.
Russell-Jones R; Fraser-Andrews E; Spittle M; Whittaker S
Lancet; 1997 Sep; 350(9081):886. PubMed ID: 9310623
[No Abstract] [Full Text] [Related]
12. High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response.
Raphael BA; Shin DB; Suchin KR; Morrissey KA; Vittorio CC; Kim EJ; Gardner JM; Evans KG; Introcaso CE; Samimi SS; Gelfand JM; Rook AH
Arch Dermatol; 2011 Dec; 147(12):1410-5. PubMed ID: 21844430
[TBL] [Abstract][Full Text] [Related]
13. [KIR3DL2: a new step for the management of patients with Sezary syndrome].
Ortonne N; Bagot M; Bensussan A
Med Sci (Paris); 2006; 22(8-9):691-3. PubMed ID: 16962036
[No Abstract] [Full Text] [Related]
14. Sézary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and Extracorporeal Photopheresis.
Behle V; von Braunmühl T; Sayehli C; Gesierich A; Goebeler M; Geissinger E; Wobser M
Acta Derm Venereol; 2017 Aug; 97(8):973-975. PubMed ID: 28512672
[No Abstract] [Full Text] [Related]
15. Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome.
Fritz TM; Kleinhans M; Nestle FO; Burg G; Dummer R
Br J Dermatol; 1999 Jun; 140(6):1144-7. PubMed ID: 10354086
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management.
Wilcox RA
Am J Hematol; 2014 Aug; 89(8):837-51. PubMed ID: 25042790
[TBL] [Abstract][Full Text] [Related]
17. Possible benefit of oral alitretinoin in T-lymphoproliferative diseases: a report of two patients with palmoplantar hyperkeratotic-rhagadiform skin changes and mycosis fungoides or Sézary syndrome.
Molin S; Ruzicka T
Br J Dermatol; 2009 Dec; 161(6):1420-2. PubMed ID: 19785592
[No Abstract] [Full Text] [Related]
18. Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma.
Zaki MH; Wysocka M; Everetts SE; Wang KS; French LE; Ritz J; Rook AH
J Invest Dermatol; 2002 Feb; 118(2):366-71. PubMed ID: 11841558
[TBL] [Abstract][Full Text] [Related]
19. A new nail in the CTCL coffin.
Lessin SR
J Invest Dermatol; 2006 Nov; 126(11):2368-9. PubMed ID: 17041618
[TBL] [Abstract][Full Text] [Related]
20. [Item no 164: malignant lymphoma: cutaneous lymphoma].
CEDEF
Ann Dermatol Venereol; 2008 Nov; 135(11 Suppl):F160-2. PubMed ID: 18984207
[No Abstract] [Full Text] [Related]
[Next] [New Search]